Categories
Change Password!
Reset Password!
An innovative nasal dihydroergotamine system delivers sustained ease of use, strong patient satisfaction, and fast, consistent migraine relief over 12 months of real-world use.
A 12-month prospective study defines the long-term patient experience and safety profile of a novel therapy delivering 5.2 mg dihydroergotamine nasal powder (STS101) in the routine management of migraine. Researchers tracked adults aged 18–65 with a history of migraine exploring real-world use of a nasal migraine therapy. Participants were instructed to self-administer the treatment within defined daily and monthly limits, reflecting practical, everyday migraine management.
The study focused on capturing satisfaction, ease of use, likelihood to continue therapy, and comparisons with prior migraine medications at 3, 6, and 12 months. Ratings were recorded on a standardized 5-point scale. In parallel, participants logged headache pain relief and improvement of their most troublesome symptom in electronic diaries, providing an integrated view of both experiential and clinical outcomes over time.
Overall, participants reported consistently favorable impressions of STS101 across all assessment periods, with minimal decline over time (Table 1).
Exploratory efficacy analyses showed progressive improvement in symptom relief following dosing (Table 2):
They concluded that STS101 was consistently well-received over 12 months, with participants highlighting ease of use and high satisfaction. Most reported a preference over prior migraine treatments, while exploratory data confirmed rapid, reliable relief from headache pain and bothersome symptoms and also highlighted the potential of STS101 as a patient-centered option for tackling acute migraines.
Headache
Study participant impression of use and satisfaction with STS101 (dihydroergotamine nasal powder): Results from the open-label ASCEND acute migraine study
Jessica Ailani et al.
Comments (0)